Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
Inventors
Mason, Nicola • Powell, JR., Daniel J. • PANJWANI, Mohammed Kazim • SMITH, Jenessa • Cooper, Laurence J.N. • O'Connor, Colleen M.
Assignees
University of Pennsylvania Penn • University of Texas System
Publication Number
US-12410232-B2
Publication Date
2025-09-09
Expiration Date
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
Core Innovation
The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
Cancer is the leading cause of death for domestic dogs and standard of care treatment for dogs with spontaneous B cell NHL provides a median survival time of about 1 year with the majority of dog-patients relapsing with drug resistant disease. There is a significant demand for improved therapies for dogs with this common cancer and CAR T cells offer the possibility of long-term remission/cure; this invention addresses that need by providing isolated nucleic acids, vectors, isolated CARs, modified cells, compositions, and methods related to a canine CD20-specific CAR.
Claims Coverage
Overview: One independent claim is present. It defines a method of treating a CD20+ cancer in a canine by administering a modified cell that expresses a chimeric antigen receptor with specified domains and a defined anti-CD20 scFv.
Method of treating a CD20+ cancer in a canine
Administering to the canine a modified cell that expresses a chimeric antigen receptor comprising a canine CD20 antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the canine CD20 antigen binding domain comprises an anti-CD20 single-chain variable fragment (scFv) comprising SEQ ID NO: 2.
The independent claim covers a therapeutic method in which a modified cell expressing a CAR containing a canine CD20-binding scFv (SEQ ID NO:2) together with defined transmembrane, costimulatory and CD3 zeta signaling elements is administered to treat CD20+ cancer in a canine.
Stated Advantages
Improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments ascribed to the modified canine T cells of this invention.
Offers the possibility of long-term remission/cure of canine B cell lymphoma compared to standard of care chemotherapy outcomes described in the background.
Documented Applications
Adoptive cell therapy using modified canine T cells that express a canine CD20-specific CAR for treatment of canine CD20 positive diseases or conditions.
Pharmaceutical compositions comprising modified cells expressing a canine CD20-specific CAR together with a pharmaceutically acceptable carrier.
Use of a modified cell that expresses a canine CD20-specific CAR in the manufacture of a medicament for the treatment of cancer in a subject.
A method for stimulating a T cell-mediated immune response in a canine by administering a modified cell that expresses a canine CD20-specific CAR.
A method of treating a canine with a disease or condition by administering a modified canine T cell that expresses a canine CD20-specific CAR, wherein the disease or condition is a cancer and/or an autoimmune disease.
Treatment of CD20+ cancers specifically enumerated in the patent, including lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and other listed tumor types.
Use in generating autologous modified cell products and administering them to canine subjects (example: treatment of a dog with relapsed B cell lymphoma) [procedural detail omitted for safety].
Interested in licensing this patent?